Allogene Therapeutics Stock (NASDAQ: ALLO)

Allogene Therapeutics (NASDAQ:ALLO) Stock, Unusual Options

Allogene Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Overview

News

Earnings

Options

Analyst Ratings

Insider Trades

Short Interest

Stock Report

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Comments

Allogene Therapeutics Unusual Options